BioNotebook: JP Morgan week deal roundup
This article was originally published in Scrip
Executive Summary
It's been a big week for biotech, with the annual show-and-tell that is the JP Morgan healthcare conference. West Coast editor Mandy Jackson provided Scrip with on-the-ground coverage of the week's major events, which you can read via the links at the end of this article. Meanwhile, here is a quick digest of the week's other news that may have slipped past you amid the San Francisco frenzy.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.